Posted by Michael Wonder on 18 Jan 2023
Zai Lab announces inclusion of Qinlock (ripretinib) and Nuzyra (omadacycline) in China’s National Reimbursement Drug List
18 January 2023 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include both Qinlock (ripretinib) for advanced gastro-intestinal stromal tumour patients who have received prior treatment with three or more kinase inhibitors in the all-comer setting, and Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection for intravenous formulation.
In December 2021, Nuzyra was approved as a Category 1 innovative drug by the China NMPA with both oral and IV formulations, for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. It is locally manufactured in China.
In March 2021, Qinlock was approved by the NMPA for the treatment of adult patients with advanced gastro-intestinal stromal tumour who have received prior treatment with three or more kinase inhibitors, including imatinib mesylate.
